Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Phase of Trial: Phase III
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Tirzepatide (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SURPASS-4
- Sponsors Eli Lilly and Company
- 11 Dec 2018 Status changed from not yet recruiting to recruiting.
- 20 Nov 2018 Planned primary completion date changed from 15 Jun 2021 to 15 May 2021.
- 15 Nov 2018 New trial record